

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Last Update: Mar 30, 2025

A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines

ClinicalTrials.gov Identifier:

[NCT05976243](#)

Novartis Reference Number:CLOU064M12301

See if you Pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).

The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).

The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period This study consists of a core and extension periods.

The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12.

The Core period consists of:

- * Screening period (up to 4 weeks): During the screening period, participants who have provided informed consent will be assessed for study eligibility.
- * Double-blind, placebo-controlled treatment period (24 weeks): 24 weeks of double-blind treatment with remibrutinib or placebo.
- * Open-label treatment period (28 weeks): 28 weeks of open-label treatment with remibrutinib.
- * Follow-up period: 4 weeks of treatment free follow-up. The open-label extension period consists of observation and treatment period. At the end of the core period of the study, if participants continue to experience symptoms, they will transition to the treatment period in OLE. If they do not experience symptoms

they will transition to the observation period in the OLE.

The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib

Condition

Chronic Inducible Urticaria

Phase

Phase3

Overall Status

Recruiting

Number of Participants

348

Start Date

Dec 07, 2023

Completion Date

Dec 31, 2028

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

Interventions

Other

Placebo

Placebo treated groups and arms

Drug

Remibrutinib

Remibrutinib treated groups and arms

Eligibility Criteria

Inclusion Criteria for core period:

1. Male and female participants ≥ 18 years of age at the time of signing of the ICFs
2. Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
3. The following response to the provocation test for each subtype is required at the randomization visit :

* Symptomatic Dermographism: A Total Fric Score of ≥ 3 using the FricTest® 4.0 and a numerical rating scale score of ≥ 5 for itch after the provocation test.

- * Cold Urticaria: A Critical Threshold Temperature of $\geq 15^{\circ}\text{C}$ using the TempTest® 4.0 and a numerical rating scale score of ≥ 5 for itch after the provocation test.
 - * Cholinergic Urticaria: A physician global assessment of severity of hives ≥ 2 using the Pulse-controlled ergometry test and a numerical rating scale score of ≥ 5 for itch after the provocation test.
4. Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
5. Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.

Inclusion criteria for the OLE:

1. Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period

Exclusion Criteria for core period:

- * 1. Previous use of remibrutinib or other BTK inhibitors.
- 2. Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
- 3. Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
- 4. Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
- 5. Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
- 6. Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism

There are no exclusion criteria for OLE

Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1181ach,Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1414aif,Argentina

Novartis Investigative Site

Recruiting

Rosario,Santa Fe,2000,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,C1125abe,Argentina

Australia

Novartis Investigative Site

Recruiting

Carlton,Victoria,3053,Australia

Novartis Investigative Site

Recruiting

Melbourne,Victoria,3004,Australia

Novartis Investigative Site

Recruiting

Woolloongabba,Queensland,4102,Australia

Brazil

Novartis Investigative Site

Recruiting

Alphaville Barueri,Sao Paulo,06454010,Brazil

Novartis Investigative Site

Recruiting

Santo Andre,SP,09060 650,Brazil

Novartis Investigative Site

Recruiting

Sorocaba,SP,18040-425,Brazil

Canada

Novartis Investigative Site

Recruiting

Hamilton,Ontario,L8L 3C3,Canada

Novartis Investigative Site

Recruiting

Winnipeg,Manitoba,R3j 0s9,Canada

China

Novartis Investigative Site

Recruiting

Nanjing,210042,China

Novartis Investigative Site

Recruiting

Jinan,Shandong,250022,China

Novartis Investigative Site

Recruiting

Yi Wu,Zhejiang,322000,China

Novartis Investigative Site

Recruiting

Beijing,100191,China

Novartis Investigative Site

Recruiting

Chongqing,400038,China

Novartis Investigative Site

Recruiting

Jinan,250012,China

Colombia

Novartis Investigative Site

Recruiting

Barranquilla,Atlantico,080002,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

France

Novartis Investigative Site

Recruiting

Toulouse,31400,France

Novartis Investigative Site

Recruiting

Rouen,76031,France

Novartis Investigative Site

Recruiting

Montpellier,34295,France

Novartis Investigative Site

Recruiting

Nantes Cedex 1,44093,France

Novartis Investigative Site

Recruiting

Clermont Ferrand,63003,France

Novartis Investigative Site

Recruiting

Paris,75970,France

Novartis Investigative Site

Recruiting

Grenoble,38043,France

Novartis Investigative Site

Recruiting

Pierre Benite,69495,France

Germany

Novartis Investigative Site

Recruiting

Tuebingen,72076,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Dresden,01307,Germany

Novartis Investigative Site

Recruiting

Luebeck,23538,Germany

Novartis Investigative Site

Recruiting

Mainz,55131,Germany

Novartis Investigative Site

Recruiting

Muenster,48149,Germany

Novartis Investigative Site

Recruiting

Stade,21682,Germany

Novartis Investigative Site

Recruiting

Goettingen,Niedersachsen,37075,Germany

Hong Kong

Novartis Investigative Site

Recruiting

Hong Kong,Hong Kong

Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Novartis Investigative Site

Recruiting

Szolnok,5000,Hungary

India

Novartis Investigative Site

Recruiting

Bangalore,Karnataka,560004,India

Novartis Investigative Site

Recruiting

Mysore,Karnataka,570001,India

Novartis Investigative Site

Recruiting

Nagpur,Maharashtra,440015,India

Novartis Investigative Site

Recruiting

New Delhi,110029,India

Israel

Novartis Investigative Site

Recruiting

Jerusalem,9112001,Israel

Novartis Investigative Site

Recruiting

Kfar Saba,44281,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,52621,Israel

Novartis Investigative Site

Recruiting

Tel Aviv,6423906,Israel

Novartis Investigative Site

Recruiting

Haifa,3339419,Israel

Italy

Novartis Investigative Site

Recruiting

Catania,CT,95123,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00133,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20162,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20122,Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Rozzano,MI,20089,Italy

Japan

Novartis Investigative Site

Recruiting

Shinjuku Ku,Tokyo,160-0023,Japan

Novartis Investigative Site

Recruiting

Kamimashi-gun,Kumamoto,861-3106,Japan

Novartis Investigative Site

Recruiting

Kyoto,606 8507,Japan

Novartis Investigative Site

Recruiting

Tachikawa,Tokyo,190-0023,Japan

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,060-8543,Japan

Novartis Investigative Site

Recruiting

Habikino city,Osaka,583 8588,Japan

Novartis Investigative Site

Recruiting

Hiroshima,730-8518,Japan

Novartis Investigative Site

Recruiting

Bunkyo-ku,Tokyo,113-8519,Japan

Novartis Investigative Site

Recruiting

Takatsuki,Osaka,569-8686,Japan

Novartis Investigative Site

Recruiting

Izumo-city,Shimane,693 8501,Japan

Novartis Investigative Site

Recruiting

Shimotsuga Gun,Tochigi,321-0293,Japan

Novartis Investigative Site

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Fukuoka,807-8556,Japan

Korea, Republic of

Novartis Investigative Site

Recruiting

Suwon si,Gyeonggi Do,16499,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,03722,Korea, Republic of

Malaysia

Novartis Investigative Site

Recruiting

Ipoh,Perak,30450,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,Wilayah Persekutuan,50586,Malaysia

Novartis Investigative Site

Recruiting

Pulau Pinang,10990,Malaysia

Novartis Investigative Site

Recruiting

Muar,Johor,84000,Malaysia

Netherlands

Novartis Investigative Site

Recruiting

Groningen,9725 ch,Netherlands

Novartis Investigative Site

Recruiting

Utrecht,3584,Netherlands

Poland

Novartis Investigative Site

Recruiting

Bydgoszcz,85-094,Poland

Novartis Investigative Site

Recruiting

Olsztyn,10-045,Poland

Novartis Investigative Site

Recruiting

Rzeszow,35 055,Poland

Novartis Investigative Site

Recruiting

Warszawa,02-962,Poland

Portugal

Novartis Investigative Site

Recruiting

Coimbra,3000 075,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1649 035,Portugal

Novartis Investigative Site

Recruiting

Vila Nova De Gaia,4434 502,Portugal

Romania

Novartis Investigative Site

Recruiting

Bucharest,District 2,020762,Romania

Novartis Investigative Site

Recruiting

Timisoara,Timis,300566,Romania

Novartis Investigative Site

Recruiting

Brasov,500283,Romania

Novartis Investigative Site

Recruiting

Cluj Napoca,400162,Romania

Singapore

Novartis Investigative Site

Recruiting

Singapore,119074,Singapore

Novartis Investigative Site

Recruiting

Singapore,308205,Singapore

Slovakia

Novartis Investigative Site

Recruiting

Kezmarok,060 01,Slovakia

Novartis Investigative Site

Recruiting

Bratislava,84102,Slovakia

Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08003,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

Novartis Investigative Site

Recruiting

Cordoba,Andalucia,14004,Spain

Novartis Investigative Site

Recruiting

Mostoles,Madrid Comunidad De,28933,Spain

Novartis Investigative Site

Recruiting

Alicante,Comunidad Valenciana,03010,Spain

Novartis Investigative Site

Recruiting

Madrid,280796,Spain

Novartis Investigative Site

Recruiting

Valencia,Comunidad Valenciana,46015,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Santiago de Compostela,A Coruna,15702,Spain

Novartis Investigative Site

Recruiting

Granada,Andalucia,18014,Spain

Thailand

Novartis Investigative Site

Recruiting

Chiang Mai,50200,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10700,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10400,Thailand

Turkey

Novartis Investigative Site

Recruiting

Istanbul,34093,Turkey

Novartis Investigative Site

Recruiting

Istanbul,34480,Turkey

Novartis Investigative Site

Recruiting

Istanbul,34662,Turkey

Novartis Investigative Site

Recruiting

Sakarya,54290,Turkey

Novartis Investigative Site

Recruiting

Talas Kayseri,38039,Turkey

United Kingdom

Novartis Investigative Site

Recruiting

Oxford,Ox3 7le,United Kingdom

Novartis Investigative Site

Recruiting

Glasgow,G51 4tf,United Kingdom

United States

Finlay Medical Research

Recruiting

Greenacres City,Florida,33467,United States

Danelis Sanchez Perez

Phone: [561-766-2181](#)

Email: dsanchezperez@finlaymr.com

STAAMP Research LLC

Recruiting

San Antonio,Texas,78229,United States

Mario Perez

Phone: [210-851-8682](#)

Email: mariop@staampresearch.com

Erika Gonzalez

Asthma and Allergy Associates P C

Recruiting

Colorado Springs,Colorado,80907,United States

Daniel Soteres

Jennifer Potter

Phone: [719-473-8330](#)

Email: jpotter@aacos.com

PanAmerican Clinical Research

Recruiting

Brownsville,Texas,78520,United States

Aaron Del Rosal

Email: adelrosel@panamclinicalresearch.com

James Charles Campbell

Asthma and Allergy Center of Chicago S C

Recruiting

River Forest,Illinois,60305,United States

Rachna Shah

Phone: [708-366-9300](#)

Allergy and Asthma Specialist P S C

Recruiting

Owensboro,Kentucky,42301,United States

17/22

Andrea Arthur

Phone: [270-684-6144](#)

Email: andrea@cloremd.com

Lee Clore

Complete Dermatology

Recruiting

Sugar Land,Texas,77479,United States

Bartley Joseph Gill

The Indiana Clinical Trials Center

Recruiting

Plainfield,Indiana,46168,United States

Haley Peterson

Phone: [+1 317 837 6082](#)

Email: hpeterson@indianatrials.com

Mitchell William Smith

AeroAllergy Research Laboratories of Savannah Inc

Recruiting

Savannah,Georgia,31406,United States

Bruce Finkel

Servon Jackson

Phone: [912-356-3619](#)

Email: sjackson@coastalallergy.net

Western Sky Medical Research

Recruiting

El Paso,Texas,79924,United States

Christy Sifuentes

Phone: [915-544-2557](#)

Email: csifuentes@westernskymed.com

Florida Ctr Allergy Asthma Research

Recruiting

Aventura, Florida, 33180, United States

Phone: [305-273-2988](#)

Ileana Rodicio

Jaime Landman

Nexi Zuniga

Phone: [305-273-2988](#)

Email: nzuniga@florida-allergy.com

John Hopkins University

Recruiting

Baltimore, Maryland, 21204, United States

Phone: [410-550-2129](#)

Sarbjit S Saini

Allervie Clinical Research

Recruiting

Birmingham, Alabama, 35209, United States

John Anderson

Jonah Celeski

Phone: [205-871-9661](#)

Email: jceleski@allervie.com

Toledo Institute of Clinical Research

Recruiting

Toledo, Ohio, 43617, United States

Saima Faisal

Phone: [419-843-8815](#)

Email: saima.faisal@ohmiallergy.com

Treasure Valley Medical Research

Recruiting

Boise, Idaho, 83706, United States

Neetu Talreja

Stephanie Gil

Email: sgil@tvmedresearch.com

RFSA Dermatology

Recruiting

San Antonio, Texas, 78213, United States

Lindsey Finklea

Kern Research

Recruiting

Bakersfield, California, 93301, United States

Eric Boren

Mariya Mendoza

Phone: [661-864-7710](tel:661-864-7710)

Email: mariya.mendoza@phaseonect.com

Somnos Clinical Research

Recruiting

Lincoln, Nebraska, 68510, United States

Phone: [402-464-6139](tel:402-464-6139)

Robert J Szalewski

Vietnam

Novartis Investigative Site

Recruiting

Ho Chi Minh, 7000, Vietnam

Novartis Investigative Site

Recruiting

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](#)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](#)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05976243>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05976243>
2. #trial-eligibility
3. tel:561-766-2181
4. mailto:dsanchezperez@finlaymr.com
5. tel:210-851-8682
6. mailto:mariop@staampresearch.com
7. tel:719-473-8330
8. mailto:jpotter@aacos.com
9. mailto:adelrosel@panamclinicalresearch.com
10. tel:708-366-9300
11. tel:270-684-6144
12. mailto:andrea@cloremd.com
13. tel:+1 317 837 6082
14. mailto:hpeterson@indianatrials.com
15. tel:912-356-3619
16. mailto:sjackson@coastalallergy.net
17. tel:915-544-2557
18. mailto:csifuentes@westernskymed.com
19. tel:305-273-2988
20. tel:305-273-2988
21. mailto:nzuniga@florida-allergy.com
22. tel:410-550-2129
23. tel:205-871-9661
24. mailto:jceleski@allervie.com
25. tel:419-843-8815
26. mailto:saima.faisal@ohmialergy.com
27. mailto:sgil@tvmedresearch.com
28. tel:661-864-7710
29. mailto:mariya.mendoza@phaseonect.com
30. tel:402-464-6139
31. tel:+41613241111
32. mailto:

33. tel:1-888-669-6682

34. mailto:novartis.email@novartis.com